IMiDs in Relapsed/Refractory Multiple Myeloma

Joshua Richter, MD, and Jonathan L. Kaufman, MD, define and provide a basic understanding of relapsed/refractory multiple myeloma (RRMM).

Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM.

Drs Kaufman and Richter outline important considerations physicians should be aware of when selecting IMiD therapy for a patient with RRMM.

Two experts highlight their preferred treatment options for RRMM based on each line of therapy the patient will need.

Dr Richter explains which patients would benefit the most from using lenalidomide vs pomalidomide, while Dr Kaufman calls attention to clinical trials that support the use of pomalidomide in RRMM therapy.

Two practicing physicians discuss clinical pathways and decision-making tactics used at their respective institutions for RRMM management.

Drs Joshua Richter and Jonathan L. Kaufman consider where IMiDs fall in the RRMM treatment landscape in comparison with emerging treatment options, such as bispecific antibodies and CAR T-cell therapy.

Professional experts offer suggestions on how payers can be further educated on RRMM treatment.

Drs Richter and Kaufman conclude by discussing future promising developments in RRMM therapy.